309 related articles for article (PubMed ID: 26400758)
1. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.
Alimbetov D; Davis T; Brook AJ; Cox LS; Faragher RG; Nurgozhin T; Zhumadilov Z; Kipling D
Biogerontology; 2016 Apr; 17(2):305-15. PubMed ID: 26400758
[TBL] [Abstract][Full Text] [Related]
2. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
Yego EC; Dillman JF
Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
Singh RK; Diwan M; Dastidar SG; Najmi AK
Hum Exp Toxicol; 2018 May; 37(5):521-531. PubMed ID: 28629242
[TBL] [Abstract][Full Text] [Related]
4. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
Bauer SM; Kubiak JM; Rothbauer U; Laufer S
Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP).
Salminen A; Kauppinen A; Kaarniranta K
Cell Signal; 2012 Apr; 24(4):835-45. PubMed ID: 22182507
[TBL] [Abstract][Full Text] [Related]
6. Endoplasmic reticulum-associated ubiquitin-conjugating enzyme Ube2j1 is a novel substrate of MK2 (MAPKAP kinase-2) involved in MK2-mediated TNFα production.
Menon MB; Tiedje C; Lafera J; Ronkina N; Konen T; Kotlyarov A; Gaestel M
Biochem J; 2013 Dec; 456(2):163-72. PubMed ID: 24020373
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase activated protein kinase 2 (MK2) participates in p38 MAPK regulated control of oligodendrocyte differentiation.
Haines JD; Fang J; Mushynski WE; Almazan G
Glia; 2010 Aug; 58(11):1384-93. PubMed ID: 20607863
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors.
Williams RG; Kandasamy R; Nickischer D; Trask OJ; Laethem C; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():364-89. PubMed ID: 17110203
[TBL] [Abstract][Full Text] [Related]
9. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
Hendriks BS; Seidl KM; Chabot JR
BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
[TBL] [Abstract][Full Text] [Related]
10. Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.
Fiore M; Forli S; Manetti F
J Med Chem; 2016 Apr; 59(8):3609-34. PubMed ID: 26502061
[TBL] [Abstract][Full Text] [Related]
11. p38 MAPK signalling regulates cytokine production in IL-33 stimulated Type 2 Innate Lymphoid cells.
Petrova T; Pesic J; Pardali K; Gaestel M; Arthur JSC
Sci Rep; 2020 Feb; 10(1):3479. PubMed ID: 32103032
[TBL] [Abstract][Full Text] [Related]
12. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
[TBL] [Abstract][Full Text] [Related]
13. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting.
Gurgis FM; Ziaziaris W; Munoz L
Mol Pharmacol; 2014 Feb; 85(2):345-56. PubMed ID: 24296859
[TBL] [Abstract][Full Text] [Related]
14. Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.
Morris DL; O'Neil SP; Devraj RV; Portanova JP; Gilles RW; Gross CJ; Curtiss SW; Komocsar WJ; Garner DS; Happa FA; Kraus LJ; Nikula KJ; Monahan JB; Selness SR; Galluppi GR; Shevlin KM; Kramer JA; Walker JK; Messing DM; Anderson DR; Mourey RJ; Whiteley LO; Daniels JS; Yang JZ; Rowlands PC; Alden CL; Davis JW; Sagartz JE
Toxicol Pathol; 2010 Jun; 38(4):606-18. PubMed ID: 20448081
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.
Davis T; Bagley MC; Dix MC; Murziani PG; Rokicki MJ; Widdowson CS; Zayed JM; Bachler MA; Kipling D
Bioorg Med Chem Lett; 2007 Dec; 17(24):6832-5. PubMed ID: 17964780
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D
Sayegh S; Fantecelle CH; Laphanuwat P; Subramanian P; Rustin MHA; Gomes DCO; Akbar AN; Chambers ES
Aging Cell; 2024 Apr; 23(4):e14093. PubMed ID: 38287646
[TBL] [Abstract][Full Text] [Related]
17. p38 MAP kinase-dependent regulation of the expression level and subcellular distribution of heterogeneous nuclear ribonucleoprotein A1 and its involvement in cellular senescence in normal human fibroblasts.
Shimada N; Rios I; Moran H; Sayers B; Hubbard K
RNA Biol; 2009; 6(3):293-304. PubMed ID: 19430204
[TBL] [Abstract][Full Text] [Related]
18. The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells.
Gurgis FM; Yeung YT; Tang MX; Heng B; Buckland M; Ammit AJ; Haapasalo J; Haapasalo H; Guillemin GJ; Grewal T; Munoz L
Oncogene; 2015 May; 34(22):2934-42. PubMed ID: 25088200
[TBL] [Abstract][Full Text] [Related]
19. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts.
Lim H; Park H; Kim HP
Biochem Pharmacol; 2015 Aug; 96(4):337-48. PubMed ID: 26093063
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts.
Davis T; Brook AJ; Rokicki MJ; Bagley MC; Kipling D
Pharmaceuticals (Basel); 2016 Apr; 9(2):. PubMed ID: 27136566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
